Angelini Ventures
Strategic investment: Angelini Ventures backs Nuevocor's pioneering treatment for genetic cardiomyopathy
Angelini Ventures has co-led a $45 million Series B financing round in Nuevocor, a Singapore-based biotechnology company developing transformative therapies for genetic cardiomyopathy.
This strategic investment marks Angelini Ventures' first entry into both cardiovascular therapeutics and the Asian biotech ecosystem, while supporting Nuevocor's expansion into European clinical development.
This investment represents a significant strategic milestone for Angelini Ventures. It not only broadens our global footprint to a strategic Asian Life Sciences Hub such as Singapore but also accelerates our mission to back transformative science with the potential to impact patients worldwide,
Elia Stupka,
The collaboration highlights Angelini Ventures' commitment to supporting biotechnology innovations addressing significant unmet medical needs. Genetic cardiomyopathy affects thousands of young patients globally, with current treatments limited to heart transplantation, creating substantial healthcare system burdens.
Download the full press release to learn more about this significant partnership and Nuevocor's groundbreaking mechanobiology platform: